Nyrada (ASX:NYR) confirmed that the Nepean Hospital in New South Wales was activated as the first site in its Protect-MI phase 2a clinical trial assessing Xolatryp in potentially reducing myocardial injury, or damage to the heart muscle cells, in patients suffering a heart attack, according to a Wednesday Australian bourse filing.

The trial's primary endpoint is the safety/tolerability of the drug candidate, the filing said. Several secondary efficacy endpoints are also being evaluated, including cardiac function, extent of cardiac injury, biomarkers such as Troponin I levels, and the incidence of arrhythmias of interest.